FDA
-
-
-
-
-
-
-
Pre-Open Movers 06/18: (MGI) (PHAS) (BYND) Higher; (BHVN) (RMTI) (UBX) (more...)
-
-
-
-
-
-
-
ArQule (ARQL) Misses Q4 EPS by 1c, Revenues Beat; Offers FY19 EPS Guidance Above Consensus, FY19 Revenue Guidance Below Consensus
-
-
-
-
-
-
-
ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium
-
-
-
-
-
-
-
Pre-Open Movers 05/18: (QTNT) (AFSI) (CERN) Higher; (AGRX) (ARQL) (CPB) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Movers 11/01: (ARQL) (ADMS) (X) Higher; (EVHC) (SGRY) (DDD) Lower (more...)
-
-
-
-
-
-
-
ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

